


## PHARMACEUTICAL 2022



## Viatris Inc Rank 115 of 475







## PHARMACEUTICAL 2022



## Viatris Inc Rank 115 of 475



The relative strengths and weaknesses of Viatris Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Viatris Inc compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 204% points. The greatest weakness of Viatris Inc is the variable Cost of Goods Sold, reducing the Economic Capital Ratio by 99% points.

The company's Economic Capital Ratio, given in the ranking table, is 35%, being 311% points above the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	10,902,900
Cost of Goods Sold	12,310,800
Intangible Assets	38,247,900
Liabilities, Current	9,884,400
Liabilities, Non-Current	21,650,700
Other Assets	2,503,400
Other Compr. Net Income	-886,300
Other Expenses	1,570,100
Other Liabilities	2,815,000
Other Net Income	5,800
Property and Equipment	3,188,600
Research and Development	751,100
Revenues	17,886,300
Selling, General and Administrative Expense	4,529,200

Output Variable	Value in 1000 USD
Assets	54,842,800
Liabilities	34,350,100
Expenses	19,161,200
Stockholders Equity	20,492,700
Net Income	-1,269,100
Comprehensive Net Income	-1,712,250
Economic Capital Ratio	35%